We performed the same assays to evaluate Cyclin D2 promoter methylation in primary astrocytoma samples and found that the Cyclin D2 promoter was methylated/partially methylated in 14/44 (32%) of the tumors (Figures 7B-D) (Table 4). This evidence concerns the gene CCND2 and astrocytoma (excluding glioblastoma).